Alice Turing
For years, the honest answer to “could I be in a clinical trial?” had almost nothing to do with your diagnosis. It came down to logistics. Research ran out of academic medical centers in large cities, on a schedule the protocol set rather than one your body agreed to, and if you couldn’t manage a two-hour drive every three weeks, you weren’t eligible in any way that mattered. A lot of us have opened a trial listing, done the math on travel time and pain and unpaid time off, and quietly closed the tab.
That math is changing. A growing share of studies now run some or all of their activity away from the traditional research site, using video visits, local labs, home nursing, mailed study medication, and assessments you complete on your own phone. Researchers call these decentralized trials. In practical terms, it means the commute that used to disqualify you may no longer be part of the deal.
The trip, not the trial, is often the dealbreaker
This isn’t a hunch. In a cross-sectional survey of 1,183 people with cancer and cancer survivors published in JAMA Network Open, between 60% and 85% of respondents said they were more likely to enroll in a study when decentralization tools reduced travel and time burden. The result held across a range of different modifications, which points at something worth sitting with: for a lot of people, the obstacle was never the research. It was getting to it.
That obstacle lands hardest on people who already have the least margin. In September 2023, the National Institutes of Health designated people with disabilities a health disparity population, a formal acknowledgment that disabled people experience worse health outcomes driven by social disadvantage rather than by their conditions alone. Being systematically absent from the studies that generate treatment evidence is part of that picture. When trials mostly enroll people who can travel, the resulting data describes a healthier, wealthier, more mobile group than the one that will eventually be prescribed the drug.
What decentralized actually means
In September 2024, the U.S. Food and Drug Administration issued final guidance on decentralized trial elements, which describes how trial-related activity can take place at locations other than a traditional research site. In practice, that covers several distinct things.
Video visits replace some in-person appointments with the investigator. A traveling research nurse can come to your kitchen table for vitals, an injection, or a blood draw. Labs and imaging can be routed to a facility near you, sometimes the clinic you already use. Study medication can arrive by mail. And the questionnaires and rating scales that measure whether the treatment is working can be completed on a device instead of a clipboard in a waiting room.
Most studies don’t use all of these at once. The common model is hybrid: a handful of required on-site visits, usually clustered at the start when screening and baseline testing happen, with the bulk of the follow-up handled remotely. So when you read a listing, decentralized rarely means zero travel. It usually means much less travel, which for many of us is the whole difference between impossible and manageable.
Your symptoms are the data, and the data travels electronically
Here’s the piece that makes remote participation legitimate rather than merely convenient. If you’re not in the exam room, the study still needs a rigorous, timestamped record of how you feel and function, and that record has to survive regulatory review years later. That’s the work done by electronic clinical outcome assessment systems, which collect symptom, function, and quality-of-life measures directly from participants, clinicians, or caregivers through apps, tablets, and web portals instead of on paper gathered at a visit. Because entries are timestamped and checked for completeness as you make them, a pain rating you enter from your couch on a Tuesday morning carries the same evidentiary weight as one you’d have written down under a nurse’s supervision.
Those assessments come in a few varieties, and it’s worth knowing which one you’re being asked to complete. Patient-reported outcomes come straight from you, with no clinician filtering or interpretation. Clinician-reported outcomes are the study doctor’s professional judgment. Observer-reported outcomes are completed by a caregiver or parent when the participant can’t reliably self-report. Performance outcomes are standardized tasks, like a timed walk or a computerized cognitive test, recorded digitally. Many trials use several types together, and in a decentralized study, the patient-reported ones often carry the most weight, because they’re the measure that doesn’t require anyone else to be in the room with you.
Questions worth asking before you consent
Ask for the visit schedule broken out by location. Mostly remote is not a schedule. You want to know how many visits require travel, to where, and where they fall in the study timeline, because five site visits in the first month is a very different commitment from five spread across two years.
Ask who provides the device. FDA’s guidance states that participants who don’t own the technology a protocol specifies shouldn’t be excluded on that basis, and that sponsors should make telecommunication services available as well. Not owning a current smartphone or having patchy data is a problem for the sponsor to solve, not a reason to rule yourself out before you’ve asked.
Ask to see the app before you sign anything. Trial software is frequently built without much thought for screen readers, adjustable text size, high contrast, tremor, or limited dexterity, and a coordinator can usually give you a walkthrough or a demo login. If the assessment tool isn’t usable for you, that’s worth raising during the consent conversation rather than three weeks into daily entries.
Ask what happens when you miss entries. Fluctuating conditions mean flares, hospital stays, and days when a questionnaire is out of reach. Find out whether missed assessments affect your ability to stay in the study, and whether there’s a grace window for completing them late.
Ask about money. Data plans, home internet, and caregiver time are real costs, and some studies reimburse them, while many simply don’t mention them unless you bring them up. Raising it is a direct application of the same self-advocacy skills for chronic illness that carry you through any other medical appointment.
What decentralization doesn’t fix
Plenty of research still can’t be done from a living room. Infusions, surgical procedures, specialized imaging, and intensive safety monitoring keep some trials firmly site-based, and no amount of software changes will change that. Eligibility criteria remain a barrier too. Studies routinely exclude people with multiple conditions or complicated medication lists, which quietly filters out a lot of disabled and chronically ill candidates regardless of geography.
There’s also the burden that gets created rather than removed. Daily symptom entry for six months is work. So is troubleshooting an app, keeping a study device charged, and absorbing another stream of notifications into a life that already runs on reminders. The broader shift toward technology expanding healthcare access for disabled people is real, but it isn’t uniformly good, and a study that asks a great deal of you at home is still asking a great deal.
Saying no to a study that doesn’t fit is a legitimate answer. Declining one trial doesn’t affect your regular care and doesn’t disqualify you from a different one later.
The question is worth asking again
If you ruled out research participation years ago because the nearest site was three hours away, that ruling may simply be out of date. ClinicalTrials.gov lists studies and increasingly notes remote or hybrid designs, and a study coordinator can tell you exactly which activities require travel if you call and ask. The answer may still be no. It’s just no longer safe to assume it.
Follow me down the rabbit hole!
I'm Alice and I live with a dizzying assortment of invisible disabilities, including ADHD and fibromyalgia. I write to raise awareness and end the stigma surrounding mental and chronic illnesses of all kinds.
